ALPN — Alpine Immune Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $4.22bn
- $3.89bn
- $58.88m
- 50
- 12
- 99
- 53
Annual cashflow statement for Alpine Immune Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.9 | -27.9 | -50.3 | -57.8 | -32.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.84 | 4.51 | 7.42 | 9.22 | 2.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.2 | 52.9 | 27.3 | 4.15 | -50.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -35.3 | 30.1 | -15.2 | -43.8 | -79 |
| Capital Expenditures | -0.821 | -0.802 | -0.118 | -0.412 | -0.487 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 17.6 | -72 | -52.4 | -113 | -55.1 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | 16.8 | -72.8 | -52.5 | -113 | -55.6 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24.3 | 61.4 | 101 | 103 | 165 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.67 | 18.7 | 32.9 | -54.5 | 30.6 |